Company profile
PALVELLA THERAPEUTICS, INC.
NASDAQ:PVLABiotechnology: Pharmaceutical Preparations
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05180708 | phase3 | completed | 2021-11-29 | 2023-06-30 | Palvella Therapeutics, Inc. | A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita |
| NCT07552077 | phase2 | recruiting | 2026-04-01 | 2027-08-01 | Palvella Therapeutics, Inc. | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) |
| NCT06653842 | phase2 | active_not_recruiting | 2024-12-20 | 2025-11-21 | Palvella Therapeutics, Inc. | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations |
| NCT05643872 | phase3 | recruiting | 2022-11-15 | 2023-10-01 | Palvella Therapeutics, Inc. | A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita |
| NCT04893486 | phase2 | completed | 2021-05-06 | 2023-03-13 | Palvella Therapeutics, Inc. | CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome |
FDA applications (0)
No records yet.